How much revenue does the ultomiris drug market generate?

The market size of ultomiris drug in 2027 is calculated to be USD 7.6 billion.

What is the anticipated CAGR of the ultomiris drug industry?

Ultomiris Drug Market size was valued at USD 6.05 billion in 2026 and is anticipated to grow at a 29.04% CAGR from 2027 to 2036, reaching USD 77.45 billion by 2036.

How is expanding patient access supporting adoption of Ultomiris?

Expanded healthcare infrastructure, specialist networks, and patient access programs are reducing barriers to specialized treatment, while support initiatives improve treatment navigation, affordability, and continuity of care for eligible patients.

How are clinical trials and indication expansion shaping the long-term Ultomiris market opportunity?

Ongoing clinical research is generating evidence across related complement-mediated disorders and broader patient populations, potentially expanding the addressable treatment landscape and strengthening physician confidence as clinical development progresses.

Why does PNH remain the leading indication in the Ultomiris drug market?

PNH accounted for 51.73% of the market in 2026, supported by demand for sustained hemolysis control, reduced disease-related complications, improved diagnosis, and long-term management of this chronic complement-mediated disorder.

How is the adult patient segment driving growth in the Ultomiris drug market?

The adult segment leads demand through established clinical use, increasing diagnosis of relevant indications, greater physician familiarity with complement inhibition, and growing adoption of targeted therapies for sustained management of chronic disorders.

Why does North America dominate the Ultomiris drug market?

North America accounted for 47.7% of the market in 2026, supported by advanced healthcare infrastructure, established reimbursement systems, improved rare disease diagnosis, and access to specialized biologic therapies.

How is Asia Pacific creating growth opportunities in the Ultomiris drug market?

Asia Pacific is expected to grow fastest as improving healthcare infrastructure, rising rare disease awareness, and expanding access to innovative biologic therapies support diagnosis and treatment of complement-mediated disorders.

Who holds a significant market share in the ultomiris drug landscape?

Key players in the ultomiris drug market include AstraZeneca (UK), Alexion Pharmaceuticals (USA), Roche (Switzerland), Pfizer (USA), Novartis (Switzerland), Sanofi (France), Takeda (Japan), GSK (UK), Johnson & Johnson (USA), Bayer (Germany).